Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 451

1.

Efficacy and safety of post-docetaxel therapies in metastatic castrate-resistant prostate cancer: A systematic review of the literature.

Summers N, Vanderpuye-Orgle J, Reinhart M, Gallagher M, Sartor O.

Curr Med Res Opin. 2017 Jun 12:1-24. doi: 10.1080/03007995.2017.1341869. [Epub ahead of print]

PMID:
28604117
2.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.

Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339-X. doi: 10.1016/S1470-2045(17)30339-X. [Epub ahead of print]

PMID:
28602779
3.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ.

Lancet Oncol. 2017 Jun 2. pii: S1470-2045(17)30434-5. doi: 10.1016/S1470-2045(17)30434-5. [Epub ahead of print]

PMID:
28592386
4.

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A metaanalysis and review.

Kim JH, Kim HS, Kim BJ.

Oncotarget. 2017 May 3. doi: 10.18632/oncotarget.17594. [Epub ahead of print]

5.

Safety and efficacy evaluation of pertuzumab in patients with solid tumors.

Zhu C, Ling W, Zhang J, Gao H, Shen K, Ma X.

Medicine (Baltimore). 2017 May;96(20):e6870. doi: 10.1097/MD.0000000000006870. Review.

7.

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report.

Rahman F, Rahardjo HE, Ariwicaksono SC, Hafizar H, Sembiring MGA, Andika R, Patandung R, Hidianingsih S, Hotasi SL.

Acta Med Indones. 2017 Jan;49(1):74-78.

8.

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials.

Li A, Wei ZJ, Ding H, Tang HS, Zhou HX, Yao X, Feng SQ.

Oncotarget. 2017 Apr 13. doi: 10.18632/oncotarget.17071. [Epub ahead of print] Review.

9.

Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis.

Bergin ART, Hovey E, Lloyd A, Marx G, Parente P, Rapke T, de Souza P.

Support Care Cancer. 2017 Apr 20. doi: 10.1007/s00520-017-3706-8. [Epub ahead of print]

PMID:
28429147
10.

Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.

Ellis PM, Vella ET, Ung YC.

Clin Lung Cancer. 2017 Feb 16. pii: S1525-7304(17)30043-8. doi: 10.1016/j.cllc.2017.02.001. [Epub ahead of print] Review.

PMID:
28416123
11.

Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.

Alterio D, Cossu Rocca M, Russell-Edu W, Dicuonzo S, Fanetti G, Marvaso G, Preda L, Zorzi S, Verri E, Nole' F, Jereczek-Fossa BA.

Med Oncol. 2017 May;34(5):86. doi: 10.1007/s12032-017-0952-z. Epub 2017 Apr 8. Review.

PMID:
28391578
12.

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.

Popat S, Mellemgaard A, Reck M, Hastedt C, Griebsch I.

Future Oncol. 2017 Feb 27. doi: 10.2217/fon-2016-0493. [Epub ahead of print]

PMID:
28326832
13.

Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.

Ricci S, Stone RL, Fader AN.

Gynecol Oncol. 2017 Apr;145(1):208-216. doi: 10.1016/j.ygyno.2017.02.019. Epub 2017 Feb 13. Review.

PMID:
28209496
14.

Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.

Shamliyan TA, Middleton M, Borst C.

Clin Ther. 2017 Feb;39(2):404-427.e36. doi: 10.1016/j.clinthera.2017.01.011. Epub 2017 Feb 9. Review.

PMID:
28189362
15.

Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors.

Dreas A, Mikulski M, Milik M, Fabritius CH, Brzózka K, Rzymski T.

Curr Med Chem. 2017 Feb 3. doi: 10.2174/0929867324666170203123427. [Epub ahead of print]

PMID:
28164761
16.

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, Ibrahim M, Fergusson D, Hilton J.

Support Care Cancer. 2017 Jun;25(6):1881-1886. doi: 10.1007/s00520-017-3580-4. Epub 2017 Jan 27.

PMID:
28127659
17.

Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.

Duo-Ji MM, Ci-Ren BS, Long ZW, Zhang XH, Luo DL.

Oncotarget. 2017 Jun 6;8(23):37896-37911. doi: 10.18632/oncotarget.14664.

18.

Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Kapoor A, Wu C, Shayegan B, Rybak AP.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E414-E423. doi: 10.5489/cuaj.4112. Epub 2016 Dec 12. Review.

19.

Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.

Fu ZZ, Li K, Peng Y, Zheng Y, Cao LY, Zhang YJ, Sun YM.

Medicine (Baltimore). 2017 Jan;96(2):e5853. doi: 10.1097/MD.0000000000005853. Review.

20.

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis.

Qu CP, Sun GX, Yang SQ, Tian J, Si JG, Wang YF.

Medicine (Baltimore). 2017 Jan;96(2):e5797. doi: 10.1097/MD.0000000000005797.

Supplemental Content

Loading ...
Support Center